within Pharmacolibrary.Drugs.ATC.B;

model B01AD11
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.001983333333333333,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0062,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0036,
    k12             = 68,
    k21             = 68
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AD11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tenecteplase is a genetically engineered variant of tissue plasminogen activator (tPA) used as a thrombolytic agent. It is indicated primarily for the treatment of acute myocardial infarction (ST-segment elevation myocardial infarction, STEMI) to dissolve blood clots in coronary arteries. It is approved in many countries and used in hospital emergency settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with acute myocardial infarction after a single intravenous bolus injection.</p><h4>References</h4><ol><li><p>Wang, L, et al., &amp; Xiong, Y (2024). Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke. <i>Journal of the American Heart Association</i> 13(9) e031692–None. DOI:<a href=\"https://doi.org/10.1161/JAHA.123.031692\">10.1161/JAHA.123.031692</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38686848/\">https://pubmed.ncbi.nlm.nih.gov/38686848</a></p></li><li><p>Dittmar, E, et al., &amp; De Los Rios La Rosa, F (2023). Conversion From Intravenous Alteplase to Tenecteplase for Treatment of Acute Ischemic Stroke Across a Large Community Hospital Health System. <i>The Annals of pharmacotherapy</i> 57(10) 1147–1153. DOI:<a href=\"https://doi.org/10.1177/10600280221149409\">10.1177/10600280221149409</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36688289/\">https://pubmed.ncbi.nlm.nih.gov/36688289</a></p></li><li><p>Tanswell, P, et al., &amp; Danays, T (2002). Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. <i>Clinical pharmacokinetics</i> 41(15) 1229–1245. DOI:<a href=\"https://doi.org/10.2165/00003088-200241150-00001\">10.2165/00003088-200241150-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12452736/\">https://pubmed.ncbi.nlm.nih.gov/12452736</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AD11;
